HSPA9 and Parkinson disease: Specifically, in dopaminergic neurons, manipulations of the level of mortalin resulted in changes to the sensitivity to Parkinson’s disease phenotypes via different pathways related to OS, mitochondrial and proteasomal function [47], correlating with reduced mitochondrial membrane potential and increased production of ROS [45].